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Congestion, renal function, and electrolyte imbalance (particularly potassium) are
common problems in the management of the complex multi-morbid patient with
heart failure (HF). Poor control of these fundamental clinical features is associated
with adverse outcomes. Close monitoring of serum potassium and renal function is
recommended by most current guidelines during the management of an episode of
acute decompensated HF, yet the recommendations remain poorly implemented.
Physicians are advised to treat a state of euvolaemia after an admission with decom-
pensated HF and residual congestion is a marker of worse outcome, yet control of
congestion is poorly assessed and managed in real-world practice. This document
reﬂects the key points discussed by a panel of experts during a Heart Failure
Association meeting on physiological monitoring of the complex multi-morbid HF pa-
tient, and here, we present to aspects related to renal function, electrolyte, and
congestion monitoring.
Introduction
In heart failure (HF) one of themain reasons for hospitaliza-
tion is congestion.1,2 Both the congestion itself as well as
the diuretic drugs used to treat it can have a detrimental
impact on renal function. As such, optimized monitoring of
renal function in HF is pivotal for preventing renal failure
and emergency re-hospitalization.3,4 Unfortunately, due to
a relative lack of studies, current guidance of renal func-
tion monitoring is largely driven by clinicians’ opinions,
rather than being evidence-based.5,6
A Heart Failure Association consensus meeting was held
on the topic of physiological monitoring of the complex
multi-morbid HF patient, and one important aspect was
monitoring of the related features of congestion status,
renal function, and electrolyte levels, particularly potas-
sium. This article reflects the key points regarding potas-
sium, creatinine, and congestion assessment, discussed at
this meeting.
Importance of the kidney in heart failure
Data from international registries consistently show that
physician adherence to guideline-recommended medica-
tions (GDMT) in HF with reduced ejection fraction (HFrEF)
is associated with better outcomes.7 Unfortunately, cur-
rent HFrEF drug guidelines are not being optimally imple-
mented.8,9 Essential life-saving medications are frequently
under-used and/or under-dosed, most often because of
possibly excessive concern about adverse events.10,11
Hyperkalaemia and kidney dysfunction are common
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comorbidities in HF.12–15 Both are associated with the
underuse and under-dosing of renin–angiotensin–aldoste-
rone system inhibitors (RAASi).16,17 Loop diuretic-induced
hypokalaemia is also associated with adverse outcomes in
HFrEF.18,19 Concerns about renal adverse events may be ex-
cessive in some cases, and it should be recognized that this
has the potential of depriving patients of receiving full
doses of life-saving therapies.20,21 Down-titration of doses
or discontinuation of RAASi may be warranted temporarily
for persistent/severe hyperkalaemia, or worsening renal
function.22 However, this should not prevent attempting
re-initiation or up-titration of therapy as soon as is safely
possible.23 The use of potassium binders may facilitate up-
titration in patients prone to hyperkalaemia,24–26 although,
whether this may improve cardiovascular outcomes,
remains to be demonstrated in adequately powered out-
come trials.27,28 Importantly, guidelines recommend close
monitoring of serum potassium and renal function during
intervals after initiation of RAASi drugs.29 Unfortunately,
data from major HF registries30,31 show that such monitor-
ing is poorly implemented, even after the occurrence of
hyperkalaemia.
Monitoring of renal impairment in heart
failure
Renal failure is common in HF and impairment of renal
function is an independent marker of poor outcome.
Worsening of renal function (WRF, often defined as an in-
crease in creatinine by >0.3mg/dL) occurs more com-
monly when higher-dose diuretics are used, such as in the
high-dose limb of the DOSE-AHF trial. Although changes in
renal function can be associated with worse outcomes, this
is not always the case.32 A post hoc analysis of the DOSE-
AHF trial illustrated the diuretic-induced increase in creat-
inine did not predict worse outcomes.33 In addition, creati-
nine itself can be an unreliable marker of renal impairment
where in chronic illness muscle mass is reduced,34 which
may occur even acutely in HF.35 Baseline renal dysfunction
is an important predictor of diuretic response in WHF, sup-
porting a higher starting dose of furosemide in patients
with lower eGFR.36
The evaluation of renal function is of foremost impor-
tance in managing the complicated HF patient, especially
in the presence of advanced disease or multiple comorbid-
ities. Assessment of glomerular filtration rates (GFR) alone
is not adequate and indeed many biomarkers and imaging
techniques are available to help the clinician assess the
effects of HF and its therapy on the kidney.
Renal function decline to some extent can and must be
expected in the setting of decongestion, and accepted as
long as the overall clinical status does not deteriorate. This
is often referred to as ‘pseudo worsening renal function
(WRF)’. However, we have no robust data to define to what
degree this is acceptable. A further decline in eGFR (espe-
cially if urinary output decreases or the clinical status of a
patient simultaneously deteriorates) may represent true
WRF, which is associated with substantially worse long-
term outcomes and thusmust be avoided.37,38
Worsening of renal function should not always be seen as
a bad sign, as it can actually reflect a good response to di-
uretic therapy and an overall favourable prognosis, in what
has been coined pseudo-WRF.39 Thus the distinction be-
tween true WRF with permanent kidney damage and
pseudo-WRF which can be seen in up to one-fifth of ADHF
patients is an important thing to establish,33 especially as
being discharged with inadequate decongestion is usually
far worse than the pseudo-WRF pattern.40
Markers of renal function are suboptimal to track and de-
tect renal function decline. Creatinine tends to lag behind
renal decline, and increases in creatinine may not be
detected until 24 hours after renal function has begun to
decline. However, monitoring diuresis and daily measure-
ment of renal function and electrolytes are advocated.41–43
In routine practice, serum creatinine is the most fre-
quently used marker of renal function, and it can con-
verted to GFR by one of several formulae that have been
recommended in HF guidelines as part of routine HF care,
although the frequency of their estimation is not discussed
in detail. The Cockcroft-Gault, the simplified modification
of diet in renal disease formula and the CKD-EPI formula
have all been used to assess prognosis in HF, but their sta-
bility in the setting of acute changes that are frequent in
acutely decompensated HF is questionable. Glomerular fil-
tration rates are a measure of renal reserve capacity, but it
also includes short-term dynamic elements which help ex-
plain why it is a good predictor of long-term outcomes in
HF, but also a poor short-term predictor of hour-to-hour
changes in kidney health and how to respond clinically.
Glomerular filtration rates can be measured directly by ex-
ogenous indicator dilutor methods using agents such as
iothalamate or inulin, but it more commonly estimated
from endogenously produced factors such as creatinine or
cystatin C. Cystatin C has some advantages, for unlike cre-
atinine it is not affected by renal tubular function because
it is not secreted by the tubules.44 Serum urea, reflects
both GFR and tubular reabsorption and is thus affected by
neurohormonal status and inhibition.45 Urea is a powerful
predictor of outcome offering additional value indepen-
dent of creatinine or GFR.
Ideally, we would also have a reliable measure of renal
tubular function that can be assessed acutely during an ad-
mission for decompensated HF, and although many have
been proposed none has established a cemented role in rou-
tine practice. The most studied is neutrophil gelatinase-
associated lipocalin.46 Others include serum b2-microglubin
and fatty acid binding proteins. Urine output and electro-
lyte concentrations can and should be monitored in acute
HF,47 particularly to gauge the patient’s response to loop di-
uretic therapy. Lastly, albuminuria can be used to assess glo-
merular filtration efficacy and can be abnormal in diabetes
and CKD due to damage to the glomerular membrane.
Albuminuria is common in HF and is linked to prognosis but
the clinical implications of this remain unclear.48
Specialized imaging of the kidney, such as ultrasound,
can be helpful but is not routinely recommended and cer-
tainly not for monitoring purposes. Future techniques may
offer better insights into dynamic changes occurring in
intra-renal blood flow and the filtering tubular functions of
the kidney.
M26 P. Rossignol et al.
D
ow
nloaded from
 https://academ
ic.oup.com
/eurheartjsupp/article-abstract/21/Supplem
ent_M
/M
25/5691317 by St G
eorge's U
niversity of London user on 23 January 2020
Monitoring of electrolytes in heart failure
Electrolyte abnormalities are common in HF. They can be
the result of diuretics, renal impairment neurohormonal
activation, and the combination of these factors. Sodium
(Na) and potassium (K) are the most commonly perturbed
electrolytes49 but chloride is also affected.50 Hyponatrae-
mia is common in acutely decompensated HF.51,52 This is
thought to be the result of impaired excretion of freewater
via dilution hyponatraemia, a true depletion of sodium or
both. Potassium abnormalities are particularly due to the
treatments given for HF with hypokalaemia complicating
diuretic use and hyperkalaemia particularly associated
with increasing RAAS-blockade, along with potassium-
sparing diuretics and the sometime use of potassium sup-
plements. Magnesium, deficiency frequently co-exists with
hypokalaemia. Guidelines do not specially indicate when
or how frequently electrolytes should be monitored as it
depends on clinical circumstances, but we believe they
should be estimated daily during acute decongestive ther-
apy, during routine post-discharge follow-up and following
any dose changes in HF medication.53 All RAASi’s can in-
crease K levels but this is particularly noticeable after the
addition of mineralocorticoid receptor antagonists (MRAs).
Although the benefits of MRAs area also seen in HFrEF
patients with eGFR<60 mL/min/1.73m2, despite being as-
sociated with small acute and persistent reductions in
GFR,54 the risk of hyperkalaemia goes up when these
agents are prescribed in the presence of pre-existing renal
impairment and in such patients careful repeated estima-
tion of K is recommended.55 Newly developed oral potas-
sium binders (patiromer or zirconium cyclosilicate) might
ease long-term control of K and allow patients with HFrEF
to take higher RAASi doses than hitherto but whether this
will be reflected in improved long-term outcomes remain
unproven.
It is difficult to be prescriptive with regards to the rec-
ommended frequency of ongoing monitoring of renal func-
tion and electrolytes (usually measured together) as so
much depends on individual patient characteristics and in-
ter-current clinical events but in stable HFrEF patients it
appears reasonable to measure serum creatinine, urea,
eGFR, and electrolytes three times per year, supplemented
by re-measurement if medication or patient condition
changes.
Monitoring of congestion in heart failure
Congestion is one of the most important determinants of
HF symptoms56,57 and a major prognostic factor in HF.58–60
It is mostly treated with loop diuretics, as recommended
by major international guidelines. It is, therefore, of para-
mount importance to adequately determine the congestive
status,61 at both admission and discharge, since residual
congestion at discharge is associated to higher one-year
mortality and HF readmissions.62 Patients with residual
congestion may have been inadequately decongested dur-
ing hospitalization, or even if decongested they may expe-
rience a recurrence of congestion during post-discharge
follow-up,63 which may trigger subsequent deaths or read-
missions in the post-discharge phase.
On the one hand, inadequately low diuretic doses may
lead to persistent congestion, one major driver of the high
rate of readmission after episodes of worsening HF.
Conversely, inappropriately high loop diuretic doses may
trigger hypokalaemia and hypovolaemia, with its associ-
ated risks of worsening renal function, the latter poten-
tially leading to the down-titration or discontinuation of
life-saving drugs i.e. RAASi. Ensuring decongestion is an es-
sential goal during AHF hospitalization, but there is no
standardized method for evaluating congestion before dis-
charge and what defines adequate decongestion is cur-
rently unclear.59 Although clinical trials have proposed a
‘definition for decongestion’, assessment of decongestion
based strictly on trial pre-defined clinical signs may be nei-
ther sensitive nor specific, and has not been investigated in
real-life clinical practice.64,65 Persisting congestion should
be more aggressively addressed, perhaps even at the ex-
pense of delaying discharge, and these patients should be
more closely followed up. Furthermore, other biological
variables as surrogate markers of haemodynamic conges-
tion, a <30% change in NP concentrations, or decreased
haematocrit during hospitalization, decreasing serum os-
molality, add significant prognostic information beyond re-
sidual clinical congestion.59
Several routinely assessed biological parameters, such as
serum protein, albumin, haemoglobin,66 and haematocrit
(considered in isolation or in combination, enabling the in-
direct estimation of plasma volume)67,68 have been pro-
posed as surrogate markers of (de)congestion and have
been found to be associated with cardiovascular end-
points.28,69 The gold standard measure of haemodynamic
congestion in HF is invasive measurement of pulmonary
capillary wedge pressure1 yet this is impractical for routine
care.1 Non-invasive assessments of congestion have been
validated but with variable sensitivities and specificities.1
Physical signs of congestion can be unreliable and difficult
to assess, especially in obesity. Newer techniques such as
lung ultrasound offer advantages over older techniques in-
cluding chest X-ray.70 The reader is referred to the paper
on imaging of cardiac function for discussion of indirect es-
timation of cardiac filling pressures (Figure 1). Most guide-
lines suggest the measurement of natriuretic peptides
(NPs) in selected clinical settings, but this is more measure
of ventricular stress or dilatation than of congestion per se,
even though the two may be mechanistically linked in
many cases. NPs have a high negative predictive value for
ruling out acute HF with congestion but routine monitoring
of NP levels in long-term follow-up has not proven to be
beneficial on outcomes or cost-effective.
Other potential biomarkers of congestion that can be
monitored include sCD-14671 and the monitoring of haemo-
concentration through estimation of Hb after decongestive
therapy thereby giving an estimate of the degree of rela-
tive decongestion rather than the absolute level of conges-
tion at any point in time.72 Although increasing creatinine
levels are frequently interpreted as worsening kidney func-
tion, leading to reductions in HF therapy, during active de-
congestion an increase in creatinine is to be expected, and
being discharged with ongoing congestion seems worse
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compared with the apparent WRF as measured by tempo-
rary increases in creatinine.73
Telemedicine for monitoring congestion,
renal function, and potassium levels
Dynamic therapy optimization using a telemedicine solu-
tion based on frequent non-invasive assessments of conges-
tion (as assessed by haemoglobin), renal function, and
blood potassium may enable safe optimization of GDMT.74
Concomitant changes in haemoglobin, blood potassium,
and renal function and their interplay are probably the
most clinically relevant actionable parameters for assess-
ing congestion and the crucial cardio-renal balance. One
such system, the remote CardioRenalV
R
monitoring solution
integrates a pragmatic disease management programme
and combines the following components: (i) an innovative
microfluidics technology of accurate home monitoring of
haemoglobin, potassium, and creatinine concentrations,
using a finger-prick 3lL blood-drop; (ii) remote monitoring
using modern data transfer and data processing methods;
(iii) a comprehensive patient-centred disease manage-
ment, including a medically staffed call-centre; (iv) an in-
novative algorithmic decision support expert system
delivering personalized therapeutic advice to the physi-
cian, guided by the monitored variables and the expert sys-
tem analysis of the patients’ electronic health record.
The planned CARE-MOST HF trial (Cardiorenal Asses
sments and REmote Monitoring for the OptimiSation of
Therapy in Heart Failure) is a prospective randomized open
blinded end-point evaluation (PROBE) design trial to assess
the effectiveness of the CardiorenalV
R
telemonitoring loop
vs. usual care in the early follow-up phase of HFrEF
patients enrolled before discharge after an acute decom-
pensation. The primary end-point of the study is the cumu-
lative number of HF hospitalizations and cardiovascular
deaths. These results will shed new light on the effective-
ness of this telemonitoring system in HFrEF patients.
Conclusions
Renal function, congestion, and electrolyte disturbances
are both inter-dependent and strong predictors of outcome
in HF and can rapidly change depending on the clinical con-
text. Accurate monitoring is essential both in the dynamic
situation of acute HF as well as in up-titrating and main-
taining optimized RAASi dosages. Accurate individualized
monitoring of potassium, renal function, and congestion
can facilitate both HF therapy optimization and hospitali-
zation reduction. Telemedicine, in particular, may allow a
dynamic optimization of therapy over time. Clinical trials
specifically aimed at evaluating the optimal frequency of
renal function monitoring in patients with HF are strongly
needed.
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